Maternal thrombophilia and neonatal thrombosis

Christine Heller MD
Paediatric Haematology/Oncology, University Hospital of Frankfurt, Germany

Ulrike Nowak-Göttl* MD
Paediatric Haematology/Oncology, University Hospital of Münster, Germany

In neonates and infants, numerous clinical and environmental conditions lead to elevated thrombin generation and subsequent thrombus formation. Genetic prothrombotic defects (protein C, protein S and antithrombin deficiency, mutations of coagulation factor V and factor II, elevated lipoprotein (a)) have been established as risk factors of thromboembolic events in neonates and infants. The interpretation of the laboratory evaluation relies on age-dependent normal reference values. Because appropriate clinical trials are missing in these age groups, treatment recommendations are adapted from small-scale studies in neonates and infants and from guidelines relating to adult patient protocols. Secondary long-term anticoagulation should be administered on an individual basis.

Key words: neonatal thrombosis; underlying diseases; prothrombotic risk factors; therapy.

Thrombotic events in the neonatal period are a serious clinical condition with an estimated incidence of approximately 2.4/1000 admissions of newborns to intensive care units in the white population. Although the presentation of thrombosis is quite rare, this entity is increasing in frequency because of more sensitive diagnostic procedures and greater clinical awareness. Within the entire childhood population, possibly due to the lower concentrations of antithrombin, heparin cofactor II and protein C along with a reduced fibrinolytic capacity, neonates are at greater risk than older children of thromboembolic complications. The incidence of vascular accidents decreases significantly after the first year of life, with a second peak during puberty and adolescence, again associated with reduced fibrinolytic activity. Because of the often severe clinical manifestations in neonates with possible long-term morbidity, more studies are necessary to evaluate risks and outcome of thromboembolic events in neonates and infants.

*Corresponding author. Address: Münster Department of Paediatric Haematology and Oncology, Westfälische Wilhelms Universität, Albert Schweitzerstrasse 33, Münster, 48149, Germany. Tel.: +49-2518347783; Fax: +49-2518347828.
E-mail address: leagottl@uni-muenster.de

1521-6926/03/$ - see front matter © 2003 Elsevier Science Ltd. All rights reserved.
MATERNAL THROMBOPHILIA

Obstetric complications such as placental abruption, fetal loss and stillbirth are associated with intervillous or spiral-artery thrombosis, and placental infarction is frequently observed in low-birth-weight children. Previous work on the potential role of prothrombotic risk factors has focused mainly on the maternal side of the placenta and has shown that placental infarction and thrombosis are associated with maternal thrombophilia, i.e. antiphospholipid antibodies, hyperhomocysteinaemia, protein C deficiency, the heterozygous factor V G1691A mutation, the heterozygous factor II variant and increased Lp (a) concentrations. Besides the involvement of inherited or acquired maternal thrombophilic risk factors in fetal wastage, prematurity or intrauterine growth retardation due to placental infarction, and peripartal thromboembolic stroke, little is known so far about neonatal thromboembolism possibly associated with maternal thrombophilia. Further studies on the impact of thrombophilia on neonatal thromboembolism therefore have to take into account, in addition, potential interdependencies with maternal thrombophilia.

Pregnant women with a personal history of symptomatic thromboembolism, fetal wastage, prematurity or intrauterine growth retardation should:
- be screened for prothrombotic risk factors
- receive secondary preventive antithrombotic treatment with low-molecular weight heparin on an individual patient basis
- undergo regular ultrasound examination (e.g. in gestational weeks 10, 20, 30) to evaluate fetal growth development and to detect possible intrauterine fetal thrombus formation (caval/renal veins, cerebral arteries/veins) prior to delivery

No data are available so far with respect to the interaction of maternal and fetal prothrombotic risk factors. Therefore:
- prospective studies are recommended to evaluate the role of thrombophilia in mothers and fetuses and their possible role in obstetric complications, fetal growth restriction and/or fetal/neonatal thrombus formation
- because the role of steroid administration in inducing lung maturation as a ‘prothrombotic’ drug for the fetus is unclear, this issue should be prospectively studied

DEVELOPMENTAL HAEMOSTASIS

In general, the haemostatic system in neonates is a balanced physiological system despite low concentrations of plasma coagulation proteins with a prolonged thromboplastin time and a partial thromboplastin time. Some conditions are believed to cause a disturbance between coagulation and fibrinolysis following a prothrombotic state. It has been shown in various in vivo and in vitro studies that components of the haemostatic system, i.e. vascular endothelium, procoagulant and fibrinolytic factors, differ between infants and adults. Different coagulation factors show different
postnatal patterns of maturation. In the newborn, plasma concentrations of the vitamin K-dependent coagulation factors (II, VII, IX, X), contact factors (XI, XII, prekallikreine and high-molecular weight kininogen) are approximately 50% of adult values. These levels undergo a rapid increase in the first weeks of life, and coagulation protein values equivalent to adult values are achieved in most components by 6 months of age. In addition, the vitamin K-dependent natural inhibitors protein C and protein S are low in the neonatal period (Table 1). However, despite reduced total protein S antigen levels in neonatal plasma, a relatively high level of active protein S was found due to virtually undetectable levels of C4b-binding protein, suggesting a minimized risk of vascular accidents. Antithrombin, heparin cofactor II and protein C are reduced to approximately 50% of that of adults, whereas alpha-2 macroglobulin is increased over adult values at birth, reaching twice adult values by 6 months of age. Furthermore, the decreased capacity of newborn plasma to generate thrombin is dependent mainly on plasma concentrations of prothrombin, a fact that is therefore discussed as a source of further protection from thrombotic events during infancy and childhood. Whereas the characteristics of some components of the procoagulant coagulation system may contribute to a reduced risk of thromboembolism during infancy, there is no evidence that fibrinolytic proteins provide protection from vascular accidents in the very young. In the neonatal period, despite increased concentrations of tissue type plasminogen activator (t-PA), the decreased plasma levels and activity of plasminogen and the increased concentration of tissue type plasminogen activator inhibitors (PAI) are responsible for a hypofibrinolytic state. This situation also accounts for the prolonged thrombus lysis times observed in neonates in response to urokinase and to streptokinase and tissue type plasminogen activator (high concentrations only) administration.

| Table 1. Age-dependent reference values (median, range); healthy neonates and children. |
|---------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Factor (%) | 0–30 Days | 3 Months | 6 Months | 1–5 Years | 6–9 Years | 10–18 Years |
| Protein C-Act | 35 (14–55) | 55 (25–82) | 60 (38–95) | 75 (45–102) | 84 (64–125) | 88 (62–128) |
| Protein C Ag | 30 (12–50) | 50 (22–75) | 55 (40–100) | 70 (45–98) | 80 (55–120) | 82 (55–120) |
| Free prot. S Ag | 38 (15–55) | 55 (35–92) | 77 (45–115) | 78 (62–120) | 80 (62–130) | 85 (60–140) |
| Total prot. S Ag | 35 (14–55) | 58 (35–90) | 75 (50–110) | 85 (60–120) | 82 (59–118) | 80 (60–115) |
| Anti-thrombin | 52 (30–85) | 90 (55–120) | 98 (65–126) | 101 (85–140) | 100 (85–136) | 98 (84–139) |
| Plasminogen | 50 (35–70) | 68 (45–95) | 87 (65–100) | 98 (63–123) | 95 (68–120) | 90 (70–115) |
| Homocysteine | < 10 µmol/l |
| Lp (a) mg/dl | < (20) 30 mg/dl | > 28 |
THROMBOTIC LOCATIONS IN NEONATES AND INFANTS

The most common sources of thrombus formation in neonates (Table 2) are the renal veins, vena caval occlusion, cerebral venous thrombosis, and peripartal thromboembolic stroke. In addition, high rates of catheter-related thrombosis have been reported in neonates and infants.\(^1,2\) Further reported sources are portal and mesenteric vein thrombosis, while arterial vascular occlusions have been reported mainly as ischaemic stroke, and as catheter-related thrombosis in the aorta, the femoral artery and the subclavian artery, respectively. A further rare and life-threatening thrombotic disorder ‘purpura fulminans’, characterized by initial microvascular thrombosis in the dermis followed by perivascular haemorrhage, is observed within hours of birth in neonates with disseminated intravascular coagulation in response to septicaemia, and in babies carrying homozygous protein C deficiency or homozygous protein S deficiency.

CLINICAL SYMPTOMS AT THROMBOEMBOLIC ONSET

Clinical symptoms of deep venous thrombosis include oedema and cyanosis of the dependent limb(s), head, neck or chest, and collateral vessel circulation; abdominal mass, thrombocytopenia or haematuria give evidence of renal venous thrombosis.\(^1–4\) Acute catheter-related thrombosis includes ‘blockage’ of the central venous line (CVL) along with swelling, pain and discoloration of the involved limb, and chronic CVL-related thrombosis often presents with collateral circulation. Respiratory failure,
dyspnoea and tachypnoea give evidence of pulmonary embolism. Arterial thromboses of the limbs present clinically with cold, pale limbs along with diminished or absent pulses, diminished peripheral perfusion or reduced skin temperature. Seizures, hemiparesis and coma are leading symptoms of vascular accidents within the central nervous system in the neonate and young infant.

**DIAGNOSTIC IMAGING METHODS**

In general, the diagnostic procedures are more difficult to perform in neonates than in adult patients because of frequent clinical instability and the lack of comparable data concerning ultrasonographic scans. Duplex sonography, venography, computed tomography and magnetic resonance (MR) imaging can be used to diagnose venous thrombosis. However, venography is mandatory to confirm suspected thrombosis in the upper venous system (axillary veins, superior caval veins etc). MR imaging and MR angiography are recommended to confirm the diagnosis of thromboembolic ischaemic stroke. Ventilation/perfusion scan or MR angiography are suitable methods for diagnosing pulmonary embolism in children.

<table>
<thead>
<tr>
<th>Research agenda</th>
</tr>
</thead>
<tbody>
<tr>
<td>• controlled studies are suggested to establish ‘gold standards’ for imaging methods in neonates with thromboembolism</td>
</tr>
</tbody>
</table>

**ACQUIRED AND INHERITED PROTHROMBOTIC CONDITIONS**

Thrombus formation and thrombus growth are the result of local coagulation activation combined with a disturbance in the balance between coagulation and fibrinolysis, leading to a prothrombotic state. Numerous conditions such as peripartal asphyxia, fetal diabetes, neonatal infections, dehydration, the use of central lines, trauma or surgery, malignant diseases, renal diseases or autoimmune diseases result in elevated thrombin generation with subsequent thrombus formation in neonates and infants (Table 3; Refs. 24–30).

Various genetic defects, particularly those affecting the physiological anticoagulant systems, i.e. antithrombin, protein C, and protein S deficiency, resistance to activated protein C (APC-R) mostly due to the G1691A mutation of coagulation factor V, and the factor II G20210A gene variant, have been well established as risk factors for thrombotic events (Table 4; Refs. 31–45). In addition, metabolic diseases such as homozygous homocystinuria, and moderate hyperhomocysteinemia due to malnutrition or the common homozygous TT genotype of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism have been described, as well as increased concentrations of lipoprotein (Lp) (a), which have been recently shown significantly to enhance the risk of thromboembolic arterial and venous thrombosis in paediatric patients. Thrombophilia is a multifactorial disorder, and the presence of more than one haemostatic defect or the combination of hereditary risk factors with acquired environmental or clinical
conditions greatly increases the risk of thrombosis not only in adults but also in
neonates and infants. Moreover, acquired antiphospholipid antibodies play a potential role in the
paediatric population with symptomatic venous thrombosis\(^{49}\) or ischaemic
cerebrovascular accidents.\(^{39}\) Rare disorders of the haemostatic system, for example
dysfibrinogenaemia, hypo- or dysplasminogenaemia, heparin cofactor II deficiency,
increased levels of histidine-rich glycoprotein or further genetic polymorphisms were
also found to be associated with the risk of venous thrombosis.

### Table 3. Underlying acquired risk factors in neonates with thrombosis.

<table>
<thead>
<tr>
<th>Perinatal diseases</th>
<th>Birth asphyxia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Respiratory distress syndrome</td>
</tr>
<tr>
<td></td>
<td>Infants of diabetic mothers</td>
</tr>
<tr>
<td></td>
<td>Neonatal infections</td>
</tr>
<tr>
<td></td>
<td>Necrotising enterocolitis</td>
</tr>
<tr>
<td></td>
<td>Dehydration</td>
</tr>
<tr>
<td></td>
<td>Congenital nephritic syndrome</td>
</tr>
<tr>
<td></td>
<td>Polycytemia</td>
</tr>
<tr>
<td>Medical interventions</td>
<td>Central lines</td>
</tr>
<tr>
<td></td>
<td>Operations</td>
</tr>
<tr>
<td></td>
<td>Renal transplantation</td>
</tr>
<tr>
<td></td>
<td>Immobilization</td>
</tr>
<tr>
<td></td>
<td>Plaster casts</td>
</tr>
<tr>
<td></td>
<td>Extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>Acute diseases</td>
<td>Trauma</td>
</tr>
<tr>
<td></td>
<td>Sepsis</td>
</tr>
<tr>
<td></td>
<td>Dehydration</td>
</tr>
<tr>
<td></td>
<td>Acute rheumatic diseases</td>
</tr>
<tr>
<td></td>
<td>Nephrotic syndrome</td>
</tr>
<tr>
<td></td>
<td>Acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td>Chronic diseases</td>
<td>Malignancies</td>
</tr>
<tr>
<td></td>
<td>Renal diseases</td>
</tr>
<tr>
<td></td>
<td>Cardiac malformations</td>
</tr>
<tr>
<td></td>
<td>Chronic rheumatic diseases</td>
</tr>
<tr>
<td>Drugs</td>
<td>E. coli asparaginase</td>
</tr>
<tr>
<td></td>
<td>Prednisone</td>
</tr>
<tr>
<td></td>
<td>Coagulation factor concentrates</td>
</tr>
<tr>
<td></td>
<td>Heparins</td>
</tr>
<tr>
<td></td>
<td>Antifibrinolytic agents</td>
</tr>
</tbody>
</table>

### Practice points

- as neonatal thromboembolism is a multifactorial disorder look for underlying
diseases and prothrombotic risk factors
Screening for Prothrombotic Risk Factors in Neonates and Infants

Suitable protein-based assays for determination of APC-R, protein C, protein S and antithrombin activity, concentration of clottable fibrinogen, plasminogen activity, activities of coagulation factors VIIIIC and XII, Lp(a), histidine-rich glycoprotein, heparin cofactor II, and fasting homocysteine concentrations should be investigated along with DNA-based assays, i.e. factor V G1691A mutation, factor II G20210A variant and MTHFR C677T genotype.

A step-wise diagnostic procedure is recommended for plasma-based parameters because the corresponding antigen concentration is not reduced when the activity of a protein is within its normal range. In patients with reduced protein activity, the total and free (protein S only) protein concentration should be determined.

Besides testing for prothrombotic defects as stated above, all symptomatic neonates with thrombosis should be screened for antiphospholipid antibodies and the presence of lupus anticoagulants. In addition, because a recent prospective study on recurrent vascular occlusion after a first episode of spontaneous venous thromboembolism, i.e. thrombosis in the absence of further secondary causes, has identified a subgroup of children suffering from combined prothrombotic risk factors as being at high risk of recurrent thrombosis, a search for multiple risk factors is justified.

When Should Testing Be Done?

To prevent results of protein-based assays from being affected by the acute thrombotic onset, plasma samples should be obtained at least 3–6 months after the thrombotic episode. In addition, oral anticoagulant medication also influences protein-based assays.

<table>
<thead>
<tr>
<th>Table 4. Inherited prothrombotic risk factors.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prothrombotic risk factors</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td>Factor V G1691A gene mutation</td>
</tr>
<tr>
<td>Factor II G20210A gene mutation</td>
</tr>
<tr>
<td>Increased concentrations of apolipoprotein (a)</td>
</tr>
<tr>
<td>Moderate hyperhomocysteinemia</td>
</tr>
<tr>
<td>Homozygous C677T polymorphism in the methylenetetrahydrofolate reductase gene</td>
</tr>
<tr>
<td>Rare</td>
</tr>
<tr>
<td>Protein C deficiency</td>
</tr>
<tr>
<td>Protein S deficiency</td>
</tr>
<tr>
<td>Antithrombin deficiency</td>
</tr>
<tr>
<td>Heparin cofactor II deficiency</td>
</tr>
<tr>
<td>Very rare</td>
</tr>
<tr>
<td>Dysfibrinogenaeemia</td>
</tr>
<tr>
<td>Dys/hypoplasminogenaeae</td>
</tr>
<tr>
<td>Homozygous homocystinuria</td>
</tr>
<tr>
<td>Probably inherited</td>
</tr>
<tr>
<td>Increased levels of factor VIII, IX, or fibrinogen</td>
</tr>
<tr>
<td>Decreased levels of factor XII</td>
</tr>
</tbody>
</table>
Therefore it is recommended that fresh plasma samples for coagulation analyses should be drawn at least 14–30 days after withdrawal of oral anticoagulation. In contrast, because DNA-based assays are influenced neither by the acute thrombotic onset nor by anticoagulation and thrombolytic therapy, genotyping can be performed immediately on onset of the vascular accident. Because Lp(a) levels increase during the first year of life, reaching twofold values compared with birth values at the age of approximately 1 year, repeat testing 8–12 months after the acute thrombotic onset is mandatory when including Lp(a) in the screening program of Caucasian neonates suffering from thromboembolism.\textsuperscript{51} Repeat testing is also necessary in paediatric patients with increased anticardiolipin/antiphospholipid IgG antibodies or with lupus anticoagulants.

**CRITERIA FOR DIAGNOSIS**

For all plasma-based assays, a clotting abnormality should be documented as a defect only if the plasma level of a protein is outside the limits of its normal range (Table 1; Refs. 36,50) Besides classification based on age-dependent normal reference ranges and confirmation of a suspected protein-based prothrombotic defect in a second plasma sample, the criterion for the hereditary nature of a haemostatic risk factor is the identification of a causative gene mutation.\textsuperscript{52}

A type I deficiency state can be diagnosed when the functional plasma activity and immunological antigen concentration of a protein is below the age-related limit. A type II deficiency is present when repeatedly low functional activity levels are combined with normal antigen concentrations. As in adults\textsuperscript{52}, the diagnosis of protein S deficiency is based on reduced free protein S antigen levels combined with decreased or normal total protein S antigen concentrations in children with pre-diagnosed reduced protein S activities.

### Practice points

As the distribution of prothrombotic risk factors varies in different countries with respect to ethnic backgrounds and the number of patient/controls investigated:

- screen beyond the acute thrombotic onset for plasmatic prothrombotic risk factors
- investigate in comparison with age- and gender-matched healthy controls from the same geographic catchment areas

### Research agenda

Because there are only sparse data available to date with respect to the presence of inherited prothrombotic risk factors in paediatric populations, recommendations given in the text are restricted to white German and Austrian children with venous thrombosis or stroke.

- case–control studies are recommended for evaluating the role of prothrombotic risk factors in other populations
CLINICAL OUTCOME

Clinical follow-up studies of paediatric patients with thromboembolic vascular accidents have been reported for renal venous thrombosis, vena caval occlusion, deep venous thrombosis and pulmonary embolism. Renal venous thromboses and vena caval occlusion occurring in neonates and infants frequently persist and lead to considerable long-term morbidity with a high incidence of irreversible organ damage, i.e. residual structural abnormalities, renal function impairment and hypertension.

ANTITHROMBOTIC THERAPY IN NEONATES: GENERAL COMMENTS

Currently, only limited data are available on the treatment and prevention of thrombotic events in neonates. Thus, recommendations for antithrombotic therapy in this special patient cohort are available only from small-scale studies of children or are adapted from adult protocols. At acute onset of thrombosis, anticoagulation should be initiated to achieve patency of the occluded vessel and to prevent further thrombus growth. Anticoagulants used in neonates and infants are standard heparin, low-molecular weight heparin and thrombolytic agents. The therapeutic choice is influenced individually by the clinical situation of the child, the risk of a major bleeding complication, and the extent and location of the thrombus, respectively.

Acute thrombotic therapy

Besides specific treatment of acute thromboembolism with anticoagulant or thrombolytic therapy, infants with acute purpura fulminans due to homozygous protein C deficiency or protein S deficiency should receive fresh frozen plasma or, if available, protein C concentrate. As in adults, it has to be kept in mind that heparin administration as well as the use of thrombolytic agents can lead to major bleeding episodes or to acute thrombus rupture with subsequent pulmonary embolism or thromboembolic stroke in neonates (patent foramen ovale). In addition, heparin-induced thrombocytopenia type II has been reported not only in adults but also in paediatric patients, creating the potential need to substitute heparin with an alternative anticoagulant emergently. Although evidence-based data are missing, the management of neonates and infants with life-threatening thrombosis possibly leading to organ or limb damage necessitates acute thrombotic treatment, for example thrombolytic therapy.

Research agenda

Long-term follow-up studies are recommended to evaluate:

- the rate of secondary thrombosis.
- the development of post-thrombotic syndromes/organ damage.
Long-term antithrombotic treatment

To the current state of knowledge only few authors have reported on the outcome of paediatric patients with venous thromboembolism. Until prospective randomized data on long-term anticoagulation in neonates and infants are available, children in this age group should be treated on an individual basis. Neonates with venous thromboembolism found to have one single prothrombotic trait (one heterozygous allele: factor V 1691GA, factor II 20210GA, deficiencies of protein C, protein S or antithrombin, elevated lipoprotein (a)) should receive oral anticoagulation or low-dose heparin, usually administered for 3–6 (to 12) months after the acute thrombotic onset. For selected infants and children under long-term coumadin therapy, INR home monitoring is available. In neonates with arterial vascular occlusion or ischaemic stroke we suggest administering low-dose aspirin or LMWH.

### Practice points

- 3 months anticoagulation is suggested when the thrombus is resolved, the provoking factor is gone, and there is no further underlying prothrombotic tendency
- 6–12 (or maybe 24) months may be considered for children with ongoing underlying prothrombotic conditions, such as genetic risks, infections, inflammations or malignancies
• symptomatic neonates with severe or multiple genetic thrombotic traits (protein C, protein S, antithrombin deficiency) with spontaneous thrombosis, i.e. without further underlying prothrombotic triggering factors, or with a history of life-threatening recurrent thrombosis, long-term anticoagulant therapy with vitamin K-antagonists are considered on an individual patient basis
• secondary preventive anticoagulant therapy, e.g. low-molecular-weight heparin, may be given in situations known to provoke thrombosis

Research agenda

• prospective and randomized studies are recommended for thrombotic treatment in neonates and infants

REFERENCES


[56x308]Journal of Cardiology 1989; 344S–345S.


[64x76]: 824–834.


[73x326]1999; 88: 344S–370S.


[84x452]Pediatrics 2000; 119: 344S–370S.


